Medindia

X

Thoratec Schedules Third Quarter Conference Call, Webcast

Wednesday, October 28, 2009 General News J E 4
Advertisement


PLEASANTON, Calif., Oct. 27 Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the third quarter and first nine months of fiscal 2009 on Wednesday, November 4.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 1:30 p.m., Pacific Standard Time (4:30 p.m., Eastern Standard Time), Wednesday, November 4, hosted by Gary F. Burbach, president and chief executive officer, and David V. Smith, executive vice president and chief financial officer.

The teleconference can be accessed by calling (719) 325-4833, passcode 4647776. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available on the Internet at http://phx.corporate-ir.net/phoenix.zhtml?p=iroleventDetails&c=95989&eventID=2492660, or at http://www.thoratec.com.

A replay of the conference call will be available through Wednesday, November 11, via http://www.thoratec.com or by telephone at (719) 457-0820, passcode 4647776.

Thoratec Corporation is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS (Left Ventricular Assist System), with more than 14,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.

SOURCE Thoratec Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
CryoLife Receives FDA Approval to Begin U.S. Clini...
S
Soligenix to Present at 8th Annual BIO Investor Fo...